Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf307 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Deirdre Weymann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, BC Cancer Research Institute, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Genetic Testing, Antineoplastic Agents, Immunological. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome British Columbia/Genome Canada.
Abstract (Originalsprache)
Background
Targeted treatment or immunotherapy may yield increased, durable responses for melanoma patients. Whether patient-level benefits translate to population health is unknown. This study sought to estimate patient and population impacts of a cancer control policy that reimbursed multigene panel testing and pembrolizumab for metastatic melanoma in British Columbia, Canada.
Methods
This retrospective study examined a population-based cohort of 721 adults diagnosed with metastatic melanoma in British Columbia who received single or multigene testing between 2013 and 2018. We determined patient-level policy impacts using 1:1 genetic algorithm matching of policy-affected patients with historical control patients and Kaplan–Meier analysis and inverse probability of censoring weighted regression of 2-year health-care costs and survival times. For population-level effects, we applied interrupted time-series analysis on monthly health-care system expenditures and mortality rates, estimating autoregressive integrated moving average and generalized least squares Poisson regressions.
Results
Matched cohort analysis (control patients, n = 154; intervention patients, n = 154) found mean cumulative patient-level cost increases of CAD$53 963 (95% confidence interval [CI] = $35 641 to $72 621; P < .001) and increased survival times of 111 days (95% CI = 44 to 166 days; P < .001) over 2 years. Higher patient-level systemic therapy spending of CAD$48 890 (95% CI = $31 110 to $66 910; P < .001) drove overall cost differences. Population-interrupted time-series analysis detected an immediate, sustained increase in mean monthly health-care expenditures of CAD$1921 (95% CI = $935 to $2908; P < .001) per patient. Higher overall spending did not coincide with population-level mortality changes.
Conclusions
The policy of reimbursing multigene testing and pembrolizumab produced patient survival improvements, but selectivity of response prevented population mortality improvement. Health-care system costs statistically significantly increased at the patient and population levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Population Health Sciences, BC Cancer Research Institute, Vancouver, BC, Canada.
- Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.
- Fraser Health, Surrey, BC, Canada.
- Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Cancer Genetics and Genomics Laboratory, BC Cancer, Vancouver, BC, Canada.
- Department of Pathology, BC Cancer, Vancouver, BC, Canada.
ORCID-Profile: Deirdre Weymann, Emanuel Krebs, Samantha Pollard, Melanie McPhail, Ian Bosdet, Stephen Yip, Alison M Weppler, Aly Karsan, Helen Anderson, Tania Bubela, Michael R Law, Aaron S Kesselheim, Dean A Regier
Förderung
- Genome British Columbia/Genome Canada
Zitieren
APA
Weymann, D., Krebs, E., Pollard, S., McPhail, M., Bosdet, I., Yip, S., Weppler, A. M., Karsan, A., Anderson, H., Bubela, T., Law, M. R., Kesselheim, A. S., & Regier, D. A. (2026). Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf307
Vancouver
Weymann D, Krebs E, Pollard S, McPhail M, Bosdet I, Yip S, et al. Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf307
BibTeX
@article{Weymann2026,
author = {Weymann, Deirdre and Krebs, Emanuel and Pollard, Samantha and McPhail, Melanie and Bosdet, Ian and Yip, Stephen and Weppler, Alison M and Karsan, Aly and Anderson, Helen and Bubela, Tania and Law, Michael R and Kesselheim, Aaron S and Regier, Dean A},
title = {Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf307}
}
EUVIMED